Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-09
2011-08-09
Blanchard, David J. (Department: 1619)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388750, C424S130100, C424S133100, C424S141100, C424S154100, C435S069600, C435S070210
Reexamination Certificate
active
07994289
ABSTRACT:
An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.
REFERENCES:
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5968509 (1999-10-01), Gorman et al.
patent: 6706265 (2004-03-01), Gorman et al.
patent: WO 93/19196 (1993-09-01), None
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979).
Lewin et al. GENES IV, Oxford University Press, p. 810, 1990.
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Fundamental Immunology, William E. Paul, M.D. ed., 3d ed., p. 242, 1993.
Bolt. S. et al., “The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties,” Eur. J. Immunol., 23(2):403-411 (1993).
Clark M. et al., “Advantages of rat monoclonal antibodies,” Immunol. Today, 4:100-101 (1983).
Clark M.R. & H. Waldmann, “T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies,” J. Natl. Cancer Inst. 79:393-1401 (1987).
Cockett M.I. et al., “High level expression of tissue inhibitor of metalloproteinases in chinese hamster ovary cells using glutamine synthetase gene amplification,” Bio/technology, 8:662-667 (1990).
Friend P.J. et al., “Phase I study of an engineered aglycosylated humanised CD3 antibody in renal transplant rejection,” Transplantation, 68(11):1632-37 (1999).
Isaacs J.D. et al., “Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential,” J. Immunol., 148:3062-71 (1992).
Page M.J. & M.A. Sydenham, “High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells,” Biotechnology, 9:64-68 (1991).
Routledge E.G. et al., “A humanized monovalent CD3 antibody which can activate homologous complement,” Eur. J. Immunol., 21(11):2717-25 (1991).
Routledge E.G., et al., “Reshaping antibodies for therapy,” In Protein engineering of antibody molecules for prophylactic and therapeutic applications in man (ed. M. Clark) (Academic Titles, Nottingham UK), pp. 13-44 (1993).
Routledge E.G. et al., “The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody,” Transplantation, 60:847-53 (1995).
BioAnaLab Assay Development Report Study No. 09/084-001, Mar. 10, 2010.
Colman, Research in Immunology 145:33-36, 1994.
Rudikoff et al; PNAS 79:1979, 1982.
Frewin Mark
Waldmann Herman
Blanchard David J.
BTG International Limited
Finnegan Henderson Farabow Garrett & Dunner LLP
LandOfFree
Humanized anti-CD3 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-CD3 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-CD3 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745250